Validated LC-MS/MS Method for the Determination of Rosuvastatin in Human Plasma: Application to a Bioequivalence Study in Chinese Volunteers

Dujuan Zhang, Jing Zhang, Xiaoyan Liu, Chunmin Wei, Rui Zhang, Haojing Song, Han Yao, Guiyan Yuan, Benjie Wang, Ruichen Guo

.

DOI: 10.4236/pp.2011.24044                

Abstract

A sensitive and selective liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the determination of rosuvastatin in human plasma using gliclazide as an internal standard (IS). Rosuvastatin and gliclazide in plasma were extracted with ethyl acetate, separated on a C18 reversed phase column, eluted with mobile phase of acetonitrile-methanoic acid (0.1%) (60:40, v/v), ionized by positive ion pneumatically assisted electrospray and detected in the multi-reaction monitoring mode using precursor → product ions of m/z 482.1 → 258.1 for rosuvastatin and m/z 324.2 → 127.2 for IS, respectively. The calibration curve was linear (r² > 0.99, n = 5) over the concentration range of 0.1 - 60 ng/mL. The speci?city, matrix effect, recovery, sensitivity, linearity, accuracy, precision, and stabilities were validated for rosuvastatin in human plasma. In conclusion, the validation results showed that this method was sensitive, economical and less toxic and it can successfully ful?ll the requirement of bioequivalence study of rosuvastatin calcium tablets in Chinese healthy volunteers.

Keywords

Rosuvastatin, Bioequivalence, LC-MS/MS, Pharmacokinetics

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Carswell CI, Plosker GL, Jarvis B, Rosuvastatin, Drugs. 2002; 62: 2075-2085, discussion 2086-2087.
[2]	Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Medicine. 2007; 24:541-549.
[3]	McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 2008; 22: 321-338.
[4]	Crouse JR 3rd. An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. Expert Opin Drug Metab Toxicol. 2008; 4: 287-304.
[5]	Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005; 78: 330-341.
[6]	Kumar TR, Shitut NR, Kumar PK, Vinu MC, Kumar VV, Mullangi R, Srinivas NR. Determination of rosuvastatin in rat plasma by HPLC: Validation and its application to pharmacokinetic studies. Biomed Chromatogr. 2006; 20: 881-887
[7]	Gao J, Zhong D, Duan X, Chen X. Liquid chromatography/negative ion electrospray tandem mass spectrometry method for the quantification of rosuvastatin in human plasma: application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 856: 35-40.
[8]	Xu DH, Ruan ZR, Zhou Q, Yuan H, Jiang B. Quantitative determination of rosuvastatin in human plasma by liquid chromatography with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006; 20: 2369-2375.
[9]	Hull CK, Penman AD, Smith CK, Martin PD. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 772: 219-228.
[10]	Trivedi RK, Kallem RR, Mullangi R, Srinivas NR. Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study. J Pharm Biomed Anal. 2005; 39: 661- 669.
[11]	Vittal S, Shitut NR, Kumar TR, Vinu MC, Mullangi R, Srinivas NR. Simultaneous quantitation of rosuvastatin and gemfibrozil in human plasma by high-performance liquid chromatography and its application to a pharmacokinetic study. Biomed Chromatogr. 2006; 20: 1252-9
[12]	Shah Y, Iqbal Z, Ahmad L, Khan A, Khan MI, Nazir S, Nasir F. Simultaneous determination of rosuvastatin and atorvastatin in human serum using RP-HPLC/UV detection: method development, validation and optimization of various experimental parameters. J Chromatogr B Analyt Technol Biomed Life Sci. 2011; 879: 557-63.
[13]	US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry, Bioanalytical Method Validation. http://www.fda.gov/cder/guidance/index.htm
[14]	US Food and Drug Administration. Bioavailability and bioequivalence requirements; abbreviated applications; proposed revisions. Fed Regist. 1998; 63: 64222-64228.